COMPANY OVERVIEW

Phosplatin therapeutics is a clinical stage pharmaceutical company developing phosphaplatins, a family of small-molecule compounds with an attractive safety profile and unique molecular pharmacodynamic properties.

---

LOCATION

New York, NY, USA

---

THERAPEUTIC AREAS

Oncology

---

WEBSITE

https://phosplatin.com/

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

May 5, 2022

Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.

Apr 13, 2022

Phosplatin Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of PT-112 for Thymoma and Thymic Carcinoma in Collaboration with National Cancer Institute

Apr 11, 2022

Phosplatin Therapeutics Reports on PT-112's Selective Effects and Immunogenic Cell Death in Human Prostate Cancer Cell Models at the AACR Annual Meeting 2022

Mar 24, 2022

Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board

Mar 10, 2022

Phosplatin Therapeutics Presents on PT-112 at the 2022 AACR Annual Meeting: Selective Intracellular Effects Leading to Immunogenic Cell Death (ICD) in Prostate Cancer Cell Models

For More Press Releases

---